Clinical evaluation of the Roche Elecsys® CMV IgG Avidity assay

C. Vauloup-Fellous, T. Lazzarotto, M. G. Revello, L. Grangeot-Keros

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Congenital cytomegalovirus (CMV) infection has potentially severe consequences in newborns. The testing of pregnant women for CMV-specific antibodies may be useful for the identification of women at risk of transmitting the infection to the fetus. The determination of CMV IgG avidity helps to establish the timing of infection as IgG avidity matures during the course of infection. This study examines the performance of the Elecsys® CMV IgG Avidity assay using preselected samples from patients at different phases of CMV infection. The Elecsys® CMV IgG Avidity assay was tested at three sites using sequential samples from patients with recent primary CMV infection, as well as single samples from patients with recent primary or past CMV infection. The Elecsys® assay discriminated well between early (low avidity) and late (high avidity) phases of infection in sequential serum samples. Overall, 98.8 % of low-avidity samples corresponded to infection onset 90 days before sampling. The assay's sensitivity was 90-97 %, with specificity ranging from 89 to 100 %, depending on the consideration of gray-zone avidity values. Single samples from recent primary or past infection showed similar distributions of avidity results. The Elecsys® CMV IgG Avidity assay results are in agreement with preselected samples from patients with primary or past CMV infection, showing that the test is an adequate predictor of the phase of infection.

Original languageEnglish
Pages (from-to)1365-1369
Number of pages5
JournalEuropean Journal of Clinical Microbiology and Infectious Diseases
Volume33
Issue number8
DOIs
Publication statusPublished - 2014

Fingerprint

Cytomegalovirus
Cytomegalovirus Infections
Immunoglobulin G
Infection
Pregnant Women
Fetus
Newborn Infant
Antibodies
Serum

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Medicine(all)

Cite this

Clinical evaluation of the Roche Elecsys® CMV IgG Avidity assay. / Vauloup-Fellous, C.; Lazzarotto, T.; Revello, M. G.; Grangeot-Keros, L.

In: European Journal of Clinical Microbiology and Infectious Diseases, Vol. 33, No. 8, 2014, p. 1365-1369.

Research output: Contribution to journalArticle

Vauloup-Fellous, C. ; Lazzarotto, T. ; Revello, M. G. ; Grangeot-Keros, L. / Clinical evaluation of the Roche Elecsys® CMV IgG Avidity assay. In: European Journal of Clinical Microbiology and Infectious Diseases. 2014 ; Vol. 33, No. 8. pp. 1365-1369.
@article{4d0722b5c0ef47f2a3c09e21872e98d2,
title = "Clinical evaluation of the Roche Elecsys{\circledR} CMV IgG Avidity assay",
abstract = "Congenital cytomegalovirus (CMV) infection has potentially severe consequences in newborns. The testing of pregnant women for CMV-specific antibodies may be useful for the identification of women at risk of transmitting the infection to the fetus. The determination of CMV IgG avidity helps to establish the timing of infection as IgG avidity matures during the course of infection. This study examines the performance of the Elecsys{\circledR} CMV IgG Avidity assay using preselected samples from patients at different phases of CMV infection. The Elecsys{\circledR} CMV IgG Avidity assay was tested at three sites using sequential samples from patients with recent primary CMV infection, as well as single samples from patients with recent primary or past CMV infection. The Elecsys{\circledR} assay discriminated well between early (low avidity) and late (high avidity) phases of infection in sequential serum samples. Overall, 98.8 {\%} of low-avidity samples corresponded to infection onset 90 days before sampling. The assay's sensitivity was 90-97 {\%}, with specificity ranging from 89 to 100 {\%}, depending on the consideration of gray-zone avidity values. Single samples from recent primary or past infection showed similar distributions of avidity results. The Elecsys{\circledR} CMV IgG Avidity assay results are in agreement with preselected samples from patients with primary or past CMV infection, showing that the test is an adequate predictor of the phase of infection.",
author = "C. Vauloup-Fellous and T. Lazzarotto and Revello, {M. G.} and L. Grangeot-Keros",
year = "2014",
doi = "10.1007/s10096-014-2080-4",
language = "English",
volume = "33",
pages = "1365--1369",
journal = "European Journal of Clinical Microbiology and Infectious Diseases",
issn = "0934-9723",
publisher = "Vieweg",
number = "8",

}

TY - JOUR

T1 - Clinical evaluation of the Roche Elecsys® CMV IgG Avidity assay

AU - Vauloup-Fellous, C.

AU - Lazzarotto, T.

AU - Revello, M. G.

AU - Grangeot-Keros, L.

PY - 2014

Y1 - 2014

N2 - Congenital cytomegalovirus (CMV) infection has potentially severe consequences in newborns. The testing of pregnant women for CMV-specific antibodies may be useful for the identification of women at risk of transmitting the infection to the fetus. The determination of CMV IgG avidity helps to establish the timing of infection as IgG avidity matures during the course of infection. This study examines the performance of the Elecsys® CMV IgG Avidity assay using preselected samples from patients at different phases of CMV infection. The Elecsys® CMV IgG Avidity assay was tested at three sites using sequential samples from patients with recent primary CMV infection, as well as single samples from patients with recent primary or past CMV infection. The Elecsys® assay discriminated well between early (low avidity) and late (high avidity) phases of infection in sequential serum samples. Overall, 98.8 % of low-avidity samples corresponded to infection onset 90 days before sampling. The assay's sensitivity was 90-97 %, with specificity ranging from 89 to 100 %, depending on the consideration of gray-zone avidity values. Single samples from recent primary or past infection showed similar distributions of avidity results. The Elecsys® CMV IgG Avidity assay results are in agreement with preselected samples from patients with primary or past CMV infection, showing that the test is an adequate predictor of the phase of infection.

AB - Congenital cytomegalovirus (CMV) infection has potentially severe consequences in newborns. The testing of pregnant women for CMV-specific antibodies may be useful for the identification of women at risk of transmitting the infection to the fetus. The determination of CMV IgG avidity helps to establish the timing of infection as IgG avidity matures during the course of infection. This study examines the performance of the Elecsys® CMV IgG Avidity assay using preselected samples from patients at different phases of CMV infection. The Elecsys® CMV IgG Avidity assay was tested at three sites using sequential samples from patients with recent primary CMV infection, as well as single samples from patients with recent primary or past CMV infection. The Elecsys® assay discriminated well between early (low avidity) and late (high avidity) phases of infection in sequential serum samples. Overall, 98.8 % of low-avidity samples corresponded to infection onset 90 days before sampling. The assay's sensitivity was 90-97 %, with specificity ranging from 89 to 100 %, depending on the consideration of gray-zone avidity values. Single samples from recent primary or past infection showed similar distributions of avidity results. The Elecsys® CMV IgG Avidity assay results are in agreement with preselected samples from patients with primary or past CMV infection, showing that the test is an adequate predictor of the phase of infection.

UR - http://www.scopus.com/inward/record.url?scp=84903821536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903821536&partnerID=8YFLogxK

U2 - 10.1007/s10096-014-2080-4

DO - 10.1007/s10096-014-2080-4

M3 - Article

C2 - 24584693

AN - SCOPUS:84903821536

VL - 33

SP - 1365

EP - 1369

JO - European Journal of Clinical Microbiology and Infectious Diseases

JF - European Journal of Clinical Microbiology and Infectious Diseases

SN - 0934-9723

IS - 8

ER -